Prognostic Factors and Survival in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: a Multi-Center Retrospective Analysis
DOI:
https://doi.org/10.52787/agl.v55i2.482Keywords:
Adenocarcinoma, survival, chemotherapyAbstract
Introduction. Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a five-year survival rate of less than 10%. Most patients are diagnosed at advanced stages, and both incidence and mortality are expected to rise over the next decade.
Objectives. To estimate overall survival in patients undergoing surgery for pancreatic ductal adenocarcinoma and to analyze associated clinicopathological factors.
Materials and methods. A multicenter, retrospective cohort study was conducted. Patients who underwent surgery between January 2019 and December 2024 with histologically confirmed pancreatic ductal adenocarcinoma were included. Factors associated with overall survival were identified through multivariate analysis using Cox proportional hazards regression.
Results. A total of 122 patients were evaluated. The mean age was 66.6 years, and 53.3% were female. Postoperative chemotherapy was administered in 62.3% of cases. The median overall survival was 31.7 months. Tumor recurrence occurred in 28.7% of patients, and 31.1% experienced postoperative complications. Multivariate analysis revealed that adjuvant chemotherapy was significantly associated with reduced mortality risk (HR 0.09; 95% CI: 0.04-0.21; p < 0.001). Tumor recurrence (HR 2.5; 95% CI: 1.25-5.03; p = 0.01) and histological tumor differentiation (HR 2.2; 95% CI: 1.21-4.00; p = 0.01) were associated with increased mortality.
Conclusion. Surgery combined with adjuvant chemotherapy is significantly associated with improved survival in patients with pancreatic ductal adenocarcinoma. Conversely, tumor recurrence and histological tumor differentiation are linked to decreased survival.
References
-1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
-2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21.
-3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
-4. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.
-5. Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42(1):8-18.
-6. Isaji S, Mizuno S, Windsor J, Bassi C, Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11.
-7. Van Dam J, Janssen Q, Besselink M, Homs M, Hjalmar C, Van Santvoort D, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials. Eur J Cancer. 2022;160:140-9.
-8. O’Reilly D, Fou L, Hasler E, Hawkins J, O’Connell S, Pelone F, et al. Diagnosis and management of pancreatic cancer in adults: a summary of guidelines from the UK National Institute for Health and Care Excellence. Pancreatology. 2018;18(8):962-70.
-9. Boggi U, Kauffmann EF, Napoli N, et al. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Updates Surg. 2024;76(1):1-15.
-10. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333-48.
-11. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691-703.
-12. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15(6):2403-13.
-13. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 2007;297(3):267-77.
-14. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25.
-15. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-406.
-16. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM. Clinical and economic validation of the international study group of pancreatic fistula (ISGPF) classification scheme. Ann Surg. 2007;245(3):443-51.
-17. Murimwa G, Karalis J, Meier J, et al. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. J Surg Oncol. 2023;128(4):540-8.
-18. Loss M, Konin A, Von Winkler N, et al. Completion pancreatectomy after pancreatoduodenectomy. Ann Surg. 2023;279(1):e87-93.
-19. Strobel O, Neoptolemos J, Jager D, Buchler M. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11-26.
-20. Okosaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55(4):369-82.
-21. Javed A, Mahmud O, Fatimi A, et al. Predictors for long-term survival after resection of pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2024;31(2):123-34.
-22. Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front Oncol. 2021;11:688377.
-23. Mahmud O, Javed A, Fatimi A, Habib A, Grewal M, He J, et al. ASO Author Reflections: The role of established prognostic factors in long term survival after resection of pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2024;31(2):e101-3.
-24. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, et al. Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure. Surgery. 2012;152(3 Suppl 1):S43-9.
-25. Sancio JB, Campanati R, Do Prado Lima L, Rubiao F, De Freitas J, Correa de Melo F, et al. Preoperative prognostic factors in patients with ductal adenocarcinoma of the head of the pancreas. Rev Col Bras Cir. 2020;47:e20202513.
-26. Daamen L, Groot VP, Besselink MG, et al. Detection, treatment, and survival of pancreatic cancer recurrence in the Netherlands: A nationwide analysis. Ann Surg. 2022;275(5):769-75.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sofía Gamboa Miño, Gustavo Kohan, Rodrigo Vergara Sandoval, Josefina Dib Hasan, Aldana Iaccarino, Frank Deroi Sánchez, Eduardo J. Houghton
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
